10-Q: DaVita Inc. Reports Second Quarter 2024 Results, Impacted by Change Healthcare Cyberattack

DaVita Inc.'s second quarter results were impacted by the Change Healthcare cyberattack, which caused billing and collection delays, but the company also saw growth in treatment volumes and revenue per treatment.

Summary

• DaVita Inc. reported its second quarter 2024 results, which were affected by the Change Healthcare cyberattack that disrupted claims processing and caused significant cash flow issues.
• The company experienced a reduction in cash flow due to the inability to submit payment claims through Change Healthcare's platform, leading to an increase in days sales outstanding (DSO).
• Despite the challenges, DaVita saw an increase in treatment volumes compared to the first quarter of 2024, driven by census gains.
• The company's U.S. dialysis average patient service revenue per treatment increased due to normal seasonal improvements and increases in average reimbursement rates.
• DaVita also continued to implement cost-saving initiatives to mitigate cost and volume pressures.
• The company finalized a settlement agreement with the government and a relator in a qui tam matter related to a 2017 investigation, with a settlement amount of $34.487 million.
• DaVita repurchased 4,774,415 shares of its common stock during the six months ended June 30, 2024.
• The company's international operations saw revenue growth due to acquired and non-acquired treatment growth and average reimbursement rate increases in certain countries.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects like increased treatment volumes and revenue per treatment, the significant negative impact of the Change Healthcare cyberattack, rising costs, and ongoing legal issues temper the overall sentiment. The company is facing significant challenges, and the future outlook is uncertain.

Positives

• Treatment volumes increased in the second quarter of 2024 compared to the first quarter of 2024.
• Average patient service revenue per treatment increased in the U.S. dialysis business.
• The company is implementing cost-saving initiatives to mitigate cost and volume pressures.
• International operations experienced significant revenue growth.
• The company successfully extended the maturity date of a portion of its Term Loan B-1, improving its debt profile.
• DaVita has resumed claims submissions through Change Healthcare's platform, although payment collection delays persist.

Negatives

• The Change Healthcare cyberattack caused significant disruptions to billing and collections, leading to cash flow issues and increased DSO.
• The company continues to experience elevated mortality rates among its patient population, impacting treatment volumes.
• Operating expenses increased due to higher staffing, labor, and supply costs.
• The company incurred debt prepayment, extinguishment and modification costs of $9.732 million in the second quarter of 2024.
• The company's IKC business continues to operate at a loss.
• The company is experiencing payment collection delays despite resuming claims submissions through Change Healthcare's platform.

Risks

• The ongoing impact of the Change Healthcare cyberattack on billing and collections remains a risk.
• Elevated mortality rates among patients could continue to negatively impact treatment volumes and revenue.
• Rising labor and supply costs could put pressure on profitability.
• The company faces potential risks from new or changing regulations, including those related to non-compete agreements.
• There is a risk of future supply chain shortages and disruptions.
• The company's information technology systems or proprietary information may have been compromised through the Change Healthcare cyberattack.
• The company may not be able to generate or access sufficient cash in the future to service its indebtedness or to fund its other liquidity needs.

Future Outlook

The company expects to continue to optimize its U.S. dialysis center footprint through center mergers and/or closures and expects its center closure rates to remain at elevated levels over the remainder of 2024. The company believes that its cash flow from operations and other sources of liquidity will be sufficient to fund its scheduled debt service and other obligations for the foreseeable future, including the next 12 months.

Management Comments

• Management believes that adjusted operating income is useful to compare and evaluate performance period over period and relative to competitors.
• Management uses free cash flow to assess the company's ability to fund acquisitions and meet debt service obligations.

Industry Context

The report highlights the impact of a major cybersecurity incident on a key healthcare service provider, Change Healthcare, which underscores the vulnerability of the healthcare industry to such attacks. The report also reflects the ongoing challenges faced by dialysis providers, including rising costs, labor shortages, and the need to adapt to changing reimbursement models and regulatory environments.

Comparison to Industry Standards

• The impact of the Change Healthcare cyberattack is not unique to DaVita, as many healthcare providers were affected, highlighting a systemic vulnerability in the industry.
• DaVita's focus on cost-saving initiatives is consistent with industry trends as healthcare providers seek to manage rising expenses.
• The company's expansion in international markets is a common strategy among large dialysis providers to diversify revenue streams.
• The company's investment in integrated kidney care is in line with the industry's shift towards value-based care models.
• The company's share repurchase program is a common capital allocation strategy among publicly traded companies, including those in the healthcare sector.
• The company's debt levels and interest rate management are comparable to other large healthcare companies with significant capital expenditures.

Legal Proceedings

• The company finalized a settlement agreement with the government and a relator in a qui tam matter related to a 2017 investigation, with a settlement amount of $34.487 million.
• The company is involved in ongoing investigations by the U.S. Attorneys Office, District of New Jersey, the California Department of Insurance, the District of Columbia Office of Attorney General, and the Federal Trade Commission.
• The company is a defendant in a consolidated putative class action complaint in the matter of In re Outpatient Medical Center Employee Antitrust Litigation.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, share repurchases, and legal proceedings.
• Employees are impacted by potential changes in labor costs, unionization efforts, and the company's cost-saving initiatives.
• Patients are impacted by the company's ability to provide care, which was not impacted by the Change Healthcare cyberattack.
• Suppliers are impacted by the company's purchase agreements and potential supply chain disruptions.
• Creditors are impacted by the company's debt levels and ability to meet its obligations.

Next Steps

• The company will continue to optimize its U.S. dialysis center footprint through center mergers and/or closures.
• The company will continue to implement cost-saving initiatives.
• The company will continue to monitor and address the impact of the Change Healthcare cyberattack.
• The company will continue to engage with its teammates at clinics where union petitions have been filed.

Key Dates

Keywords

dialysis, healthcare, cyberattack, revenue, treatment volume, Change Healthcare, debt, acquisitions, integrated kidney care, cost savings, mortality rates, reimbursement rates, non-compete agreements, supply chain, cash flow, DSO